[1] ALI HASAN EBRAHIM. Galectins in cancer: carcinogenesis, diagnosis and therapy.[J]. Annals of translational medicine, 2014, 2 9: 88. DOI:
10.3978/j.issn.2305-5839.2014.09.12[2] NANDOR GABOR THAN. Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia.[J]. Journal of Pathology and Translational Medicine, 2015, 49 3: 181-208. DOI:
10.4132/jptm.2015.02.25[3] BADER A. SALAMEH . 1H-1,2,3-Triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors[J]. Bioorganic & Medicinal Chemistry, 2010, 18 14: Pages 5367-5378. DOI:
10.1016/j.bmc.2010.05.040[4] HILDE VAN HATTUM. Tuning the Preference of Thiodigalactoside- and Lactosamine-Based Ligands to Galectin-3 over Galectin-1[J]. Journal of Medicinal Chemistry, 2013, 56 3: 1350-1354. DOI:
10.1021/jm301677r[5] KOICHI ITO. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress[J]. Angiogenesis, 2011, 14 3: 293-307. DOI:
10.1007/s10456-011-9213-5[6] PEIWEN KUO. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.[J]. Clinical Cancer Research, 2014, 20 21: 5558-5569. DOI:
10.1158/1078-0432.ccr-14-1138[7] R MUKHERJEE. Targeted inhibition of galectin 1 by thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats[J]. International Journal of Obesity, 2015, 39 9: 1349-1358. DOI:
10.1038/ijo.2015.74
